

May 07, 2026

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400051
(SYMBOL: THYROCARE)

BSE Limited
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400001
(SCRIP CODE: 539871)

Subject: Outcome of the Board Meeting held on Thursday, May 07, 2026

1. Recommendation for the payment of final dividend;
2. Appointment of M/s. Price Waterhouse Chartered Accountants LLP, as the Statutory Auditors of the Company for first term of five consecutive years;
3. Appointment of Cost Auditors for the financial year 2026-27;
4. Re-appointment of Mr. Rahul Franklin Guha (DIN:09588432), as Chairman, Managing Director & Chief Executive Officer of the Company;
5. Appointment of Mr. Uday Patel Kadam (DIN: 09277168) as an Additional Director in the category of Non-Executive, Non-Independent Director of the Company;
6. Appointment of Mr. Gaurav Verma (DIN: 11692586) as an Additional Director in the category of Non-Executive, Non-Independent Director of the Company;
7. Resignation of Mr. Dharmil Nirupam Sheth (DIN: 06999772), Non-Executive, Non-Independent Director of the Company;
8. Resignation of Dr. Dhaval Rajesh Shah (DIN: 07485688), Non-Executive, Non-Independent Director of the Company;
9. Investment in the equity shares of Think Health Diagnostics Private Limited, a Wholly Owned Subsidiary of the Company;
10. Alteration of the Memorandum of Association of the Company.

Dear Sir/Madam,

Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“**Listing Regulations**”), we wish to inform you that the Board of Directors of the Company (“**Board**”), at its meeting held today, i.e., Thursday, May 07, 2026, inter alia, considered and approved the following matters:

1. Recommendation for the payment of final dividend

The Board has recommended a final dividend of **Rs. 7.00 per equity share** for the financial year 2025–26, subject to the approval of the shareholders at the ensuing Annual General Meeting (“AGM”) of the Company. The dividend, if declared, shall be paid within 30 days from the date of the AGM. The record date for determining the eligibility of members entitled to receive the dividend on equity shares will be intimated separately.

The Company has already paid an interim dividend of Rs. 7.00 per equity share (pre-bonus issue; equivalent to Rs. 2.33 per share post bonus adjustment) on equity shares of face value Rs. 10 each for the financial year 2025-26. Accordingly, the total dividend for the financial year ended March 31, 2026, would aggregate to Rs. 9.33 per equity share (post bonus adjustment) on equity shares of face value Rs. 10 each, subject to approval of the final dividend by the shareholders.

2. Appointment of M/s. Price Waterhouse Chartered Accountants LLP, as the Statutory Auditors of the Company for first term of five consecutive years;

Based on the recommendation of the Audit Committee, the Board has considered and approved, and further recommended to the shareholders for their approval at the ensuing Annual General Meeting (“AGM”), the appointment of **M/s. Price Waterhouse Chartered Accountants LLP** (ICAI Firm Registration No. 012754N/N500016) as the Statutory Auditors of the Company for first term of five consecutive years, commencing from the conclusion of the 26th AGM (to be held in the calendar year 2026) until the conclusion of the 31st AGM (to be held in the calendar year 2031), subject to the approval of the shareholders and other applicable statutory requirements.

It is further informed that **M/s. M S K A & Associates LLP**, Chartered Accountants (ICAI Firm Registration No. 105047W/W101187), the existing Statutory Auditors of the Company, who were appointed for a first term of five (5) consecutive years at the 21st AGM held on June 26, 2021, shall complete their term at the conclusion of the 26th AGM of the Company to be held in the calendar year 2026.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 1.**

3. Appointment of Cost Auditors for the financial year 2026-27

Based on the recommendation of the Audit Committee, the Board has approved the appointment of **M/s. Jitender Navneet & Co.**, Cost Accountants (FRN: 000119), as the Cost Auditor of the Company for the Financial Year 2026-27.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 2.**

4. Re-appointment of Mr. Rahul Franklin Guha, (DIN: 09588432) as Chairman, Managing Director & CEO of the Company

Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the re-appointment of Mr. Rahul Franklin Guha (DIN: 09588432) as Chairman, Managing Director & Chief Executive Officer of the Company, for a further period of five (5) years commencing from May 4, 2027 to May 3, 2032 (both days inclusive), subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. He shall not be liable to retire by rotation.

Further, in terms of the respective circular(s) dated June 20, 2018, issued by BSE Limited, Ref. No. LIST/COMP/14/2018-19 and by National Stock Exchange of India Limited, Ref. No. NSE/CML/2018/24, it is hereby confirmed that Mr. Rahul Franklin Guha is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India (“SEBI”) or any other statutory authority/ court.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 3.**

5. **Appointment of Mr. Uday Patel Kadam (DIN: 09277168) as an Additional Director in the category of Non-Executive, Non-Independent Director of the Company**

Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Uday Patel Kadam (DIN: 09277168) as an Additional Director in the category of Non-Executive, Non-Independent Director on the Board of the Company with effect from May 8, 2026. He shall be liable to retire by rotation, and his appointment is subject to the approval of the shareholders of the Company within three months from the effective date of appointment.

Further, in terms of the respective circulars dated June 20, 2018, issued by BSE Limited (Ref. No. LIST/COMP/14/2018-19) and National Stock Exchange of India Limited (Ref. No. NSE/CML/2018/24), it is hereby confirmed that Mr. Uday Patel Kadam is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India ("SEBI") or any other statutory authority/court.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 4**.

6. **Appointment of Mr. Gaurav Verma (DIN: 11692586) as an Additional Director in the category of Non-Executive, Non-Independent Director of the Company**

Based on the recommendation of the Nomination and Remuneration Committee, the Board has approved the appointment of Mr. Gaurav Verma (DIN: 11692586) as an Additional Director in the category of Non-Executive, Non-Independent Director on the Board of the Company with effect from May 8, 2026. He shall be liable to retire by rotation, and his appointment is subject to the approval of the shareholders of the Company within three months from the effective date of appointment.

Further, in terms of the respective circulars dated June 20, 2018, issued by BSE Limited (Ref. No. LIST/COMP/14/2018-19) and National Stock Exchange of India Limited (Ref. No. NSE/CML/2018/24), it is hereby confirmed that Mr. Gaurav Verma is not debarred from holding the office of Director by virtue of any order passed by the Securities and Exchange Board of India ("SEBI") or any other statutory authority/court.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 5**.

7. **Resignation of Mr. Dharmil Nirupam Sheth (DIN: 06999772), Non-Executive, Non-Independent Director of the Company**

The Board took note of the resignation of Mr. Dharmil Nirupam Sheth (DIN: 06999772), Non-Executive, Non-Independent Director of the Company, who has tendered his resignation due to pre-occupation and other commitments, with effect from the close of business hours on May 07, 2026.

A copy of the resignation letter received from Mr. Dharmil Nirupam Sheth is enclosed as **Annexure 6**.

The Company has also received confirmation from Mr. Dharmil Nirupam Sheth that there are no material reasons for his resignation other than those stated in his resignation letter dated April 30, 2026.

Tests you can trust

Consequent to his resignation, he shall also cease to be a member of the following Committees of the Board:

- Nomination and Remuneration Committee
- Stakeholders' Relationship Committee
- Risk Management Committee

The Board placed on record its sincere appreciation for the valuable contributions made by Mr. Dharmil Nirupam Sheth during his tenure.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 7.**

8. Resignation of Dr. Dhaval Rajesh Shah (DIN: 07485688), Non-Executive, Non-Independent Director of the Company

The Board took note of the resignation of Dr. Dhaval Rajesh Shah (DIN: 07485688), Non-Executive, Non-Independent Director of the Company, who has tendered his resignation due to pre-occupation and other commitments, with effect from the close of business hours on May 07, 2026.

A copy of the resignation letter received from Dr. Dhaval Rajesh Shah is enclosed as **Annexure-8.**

The Company has also received confirmation from Dr. Dhaval Rajesh Shah that there are no material reasons for his resignation other than those stated in his resignation letter dated April 30, 2026.

Consequent to his resignation, he shall also cease to be a member of the Corporate Social Responsibility Committee of the Board.

The Board placed on record its sincere appreciation for the valuable contributions made by Dr. Dhaval Rajesh Shah during his tenure.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 9.**

9. Investment in the equity shares of Think Health Diagnostics Private Limited, a Wholly Owned Subsidiary of the Company

The Board has approved an investment by way of subscription to the equity shares of Think Health Diagnostics Private Limited ("Think Health"), a wholly owned subsidiary of the Company, for an amount not exceeding Rs. 5,50,00,000 (Rupees Five Crores Fifty Lakhs only), in one or more tranches, in compliance with applicable laws.

Disclosure of information pursuant to Regulation 30 of Listing Regulations, read with SEBI Master Circular No. SEBI/HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, is annexed as **Annexure- 10.**

10. Alteration of the Memorandum of Association of the Company

The Board has approved the alteration of the Memorandum of Association (“MOA”) of the Company, subject to the approval of the shareholders and such other statutory/regulatory approvals, as may be required.

The existing MOA is based on the provisions of the erstwhile Companies Act, 1956 and requires alignment with the provisions of the Companies Act, 2013. Accordingly, the proposed amendments include updating references and relevant clauses in line with the Companies Act, 2013.

Further, while the existing Objects Clause already covers diagnostic activities, it is proposed to broaden its scope by inserting an enabling sub-clause under Clause III(A) to permit the Company to undertake a wider range of activities within the healthcare and diagnostics ecosystem, including allied services and dealing in related products, equipment, and consumables.

Accordingly, the following key changes are proposed in the MOA:

Particulars	Existing Clauses	Proposed Amendments
Substitution of heading of Clause III(A)	MAIN OBJECTS OF THE COMPANY TO BE PURSUED BY THE COMPANY ON ITS INCORPORATION	THE OBJECTS TO BE PURSUED BY THE COMPANY ARE
Addition of Sub clause 1B under Clause III(A)(1)		1B To carry on the business of establishing, setting up, acquiring, operating, managing or administering diagnostic facilities (including home collection), including but not limited to, clinical laboratories, radiology and pathology centres, collection centres, hospitals, clinics, polyclinics, research and healthcare facilities, and to provide healthcare and diagnostic services including pathological, radiological, biochemical, microbiological, immunological, genetic, cardiological and other medical investigations and testing services, and to undertake collection, handling, storage, transportation, processing and analysis of human, animal, plant, food, water, soil and other samples, tissues, body fluids, blood and allied materials for diagnostic, therapeutic, research or other purposes, in India or abroad, under its own brand or otherwise, including through online or digital platforms; and to develop, operate and manage healthcare, diagnostic and data-driven digital platforms, applications and portals; and to undertake teaching, training and imparting practical and theoretical knowledge in diagnostics, pathology, healthcare and allied fields; and further to manufacture, produce, assemble, process, procure, purchase, import, export, stock, distribute, market, sell, resell, lease, hire or otherwise deal in medical, diagnostic, healthcare, pharmaceutical, surgical, wellness equipment, devices, instruments, consumables, merchandise and allied products, including point of care devices, and to carry on such activities either on its own or in collaboration with third parties, partners, franchisees or service providers in India or abroad.
Substitution of heading of Clause III(B)	Object incidental or ancillary to the	Matters which are necessary for furtherance of the objects specified in Clause III(A) are:

Tests you can trust

	attainment of main objects:	
Deletion of header of Clause III(C) i.e., "Other Objects"	Other Objects:	Deleted in line with the Companies Act, 2013, as such clauses are now covered under Clause III(B)
Substitution of Clause IV	The liability of the members is limited	The Liability of members is limited and this liability is limited to the amount unpaid, if any, on the shares held by them.
Statutory alignment	References to Companies Act, 1956	To be replaced with corresponding provisions of the Companies Act, 2013 along with necessary consequential changes

The above disclosures are also being made available on the website of the Company at <https://investor.thyrocare.com>.

The Board Meeting commenced at 03:35 P.M. and concluded at 05:40 P.M.

This is for your information and records.

Yours Faithfully,
For **Thyrocare Technologies Limited**,



Brijesh Kumar
Company Secretary and Compliance Officer
Encl. A/a

Annexure-1

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Appointment of M/s. Price Waterhouse Chartered Accountants LLP, as the Statutory Auditors of the Company for first term of five consecutive years

a)	Name of the Auditor	M/s Price Waterhouse Chartered Accountants LLP
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	<p>Appointment</p> <p>M/s. M S K A & Associates LLP, Chartered Accountants (ICAI Firm Registration No. 105047W/W101187), the current Statutory Auditors of the Company, shall complete their first term of five consecutive years at the conclusion of the 26th Annual General Meeting (“AGM”) of the Company to be held in the calendar year 2026.</p> <p>Accordingly, based on the recommendation of the Audit Committee, the Board has approved the appointment of M/s. Price Waterhouse Chartered Accountants LLP, Chartered Accountants (ICAI Firm Registration No. 012754N/N500016), - as the Statutory Auditors of the Company for a term of five consecutive years commencing from the conclusion of the 26th AGM, subject to approval of the shareholders at the ensuing AGM.</p>
c)	Date of appointment, re-appointment/cessation (as applicable) & term of appointment, re-appointment ;	Based on the recommendation of the Audit Committee, the Board has considered and approved, and further recommended to the shareholders for their approval at the ensuing Annual General Meeting (“AGM”), the appointment of M/s. Price Waterhouse Chartered Accountants LLP (ICAI Firm Registration No. 012754N/N500016) as the Statutory Auditors of the Company for first term of five consecutive years, commencing from the conclusion of the 26 th AGM (to be held in the calendar year 2026) until the conclusion of the 31 st AGM (to be held in the calendar year 2031), subject to the approval of the shareholders and other applicable statutory requirements.
d)	Brief profile (in case of appointment);	<p>M/s. Price Waterhouse Chartered Accountants LLP, (the “Firm”) having a Firm Registration No. 012754N/N500016, is a firm of Chartered Accountants registered with the Institute of Chartered Accountants of India. The Firm was established in the year 1991 and was converted into a limited liability partnership in the year 2014. The registered office of the Firm is at Sucheta Bhawan, 11A Vishnu Digambar Marg, New Delhi - 110 002 and has seventeen (17) branch offices in various cities in India.</p> <p>The Firm is primarily engaged in providing auditing and other assurance services to its clients and is a member firm of Price Waterhouse & Affiliates, a network of firms registered with the</p>

Tests you can trust

		Institute of Chartered Accountants of India having Network Registration No. NRN/E/14. Price Waterhouse & Affiliates is a network of separate, distinct and independent Indian Chartered Accountant firms, each of which is registered with the Institute of Chartered Accountants of India. The Firm has more than 125 Assurance Partners as of December 31, 2025. It has a valid peer review certificate and audits various companies listed on stock exchanges in India.
e)	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Appointment of Cost Auditors of the Company

a)	Name of the Auditor	M/s. Jitender Navneet & Co. Cost Accountants
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment
c)	Date of appointment/ re-appointment/ cessation (as applicable) & term of appointment/ re-appointment ;	Date of Appointment – May 07, 2026 Term of Appointment – For the Financial Year 2026-27
d)	Brief profile (in case of appointment);	<p>M/s. Jitender, Navneet & Co. is a firm of Cost Accountants registered with the Institute of Cost Accountants of India. The firm is engaged in the field of cost audit, management consultancy, and advisory services. It is empanelled with various regulatory and financial institutions and has experience in handling cost audits and related assignments across industries.</p> <p>The firm is also registered with the PCAOB (USA) and is empanelled with authorities such as the Income Tax Department (including for assignments under Section 142(2A) of the Income-tax Act, 1961), IFCI (for PLI schemes), and GST authorities as Special Auditors.</p> <p>The firm was established in 2003 and has carried out assignments on a pan-India basis.</p> <p>Mr. Navneet Kumar Jain, Managing Partner of the firm, is currently serving as a Member of the Central Council of the Institute of Cost Accountants of India (ICMAI).</p>
e)	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Re-Appointment of Mr. Rahul Franklin Guha (DIN: 09588432), as Chairman, Managing Director & CEO of the Company

a)	Name & Designation	Mr. Rahul Franklin Guha (DIN:09588432), Chairman, Managing Director & CEO
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Re-appointment
c)	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Effective Date of Re-Appointment – May 04, 2027 Term of re-appointment: Five (5) years (from May 4, 2027 to May 3, 2032), subject to approval of shareholders at the ensuing AGM.
d)	Brief profile (in case of appointment);	<p>Mr. Rahul Franklin Guha is the Chairman, Managing Director & Chief Executive Officer of the Company and has over 27 years of experience across healthcare, life sciences, and technology-driven businesses. He also serves as Managing Director & CEO at API Holdings Limited (the ultimate holding company), and is responsible for driving the diagnostics business across the group, including Thyrocare, and enabling synergies among group companies. He plays a key role in driving growth, operational excellence, and digital transformation initiatives.</p> <p>Prior to joining the Company, he was associated with Boston Consulting Group (BCG), where he served as Senior Partner and led the Healthcare and Life Sciences practice in India. During his tenure, he advised leading organizations on strategy, organizational transformation, and operational efficiency.</p> <p>He has also co-founded Nautilus Software Solutions and served as Chief Technology Officer at Valuepay.com, bringing strong entrepreneurial and technology leadership experience.</p> <p>Mr. Guha holds a Post Graduate Diploma in Management from the Indian Institute of Management, Bengaluru, and a Bachelor's degree in Engineering from the University of Mumbai.</p>
e)	Disclosure of relationships between directors (in case of appointment of a director).	Nil

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Appointment of Mr. Uday Patel Kadam (DIN: 09277168) as an Additional Director (Non-Executive, Non-Independent Director)

a)	Name & Designation	Mr. Uday Patel Kadam Non-Executive, Non-Independent Director
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment
c)	Date of appointment/ re-appointment/cessation (as-applicable) & term of appointment/ re-appointment ;	Date of Appointment – May 08, 2026 Term of Appointment – Not Applicable
d)	Brief profile (in case of appointment);	<p>Mr. Uday Patel Kadam is a seasoned business leader with over 18 years of diverse experience across healthcare, technology, telecom and financial services sectors, with strong expertise in business strategy, P&L management, operations and supply chain. He is currently associated with API Holdings Limited as Chief Operating Officer & Chief Business Officer, where he is responsible for driving business strategy, operational excellence and growth initiatives, with end-to-end accountability for key business verticals, including supply chain and procurement functions.</p> <p>Prior to this, he has held leadership roles at Ninjacart as Business Head – Ninja Kisaan Platform, where he played a key role in building and scaling platform-led businesses and managing large-scale supply chain operations across India. Earlier, he was associated with Bharti Airtel for over six years in various senior leadership roles across sales, marketing, finance and business operations, including Head of Sales & Distribution (Karnataka) and Chief Commercial Officer – Airtel Mumbai. He began his career with HSBC and Deutsche Bank in finance and credit risk functions. Mr. Kadam holds a Master of Business Administration (MBA) from the Indian School of Business and brings strong leadership capabilities and strategic acumen, which will be valuable to the Company.</p>
e)	Disclosure of relationships between directors (in case of appointment of a director).	Nil

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Appointment of Mr. Gaurav Verma (DIN: 11692586), as an Additional Director (Non-Executive, Non-Independent Director)

a)	Name & Designation	Mr. Gaurav Verma Non-Executive, Non-Independent Director
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Appointment
c)	Date of appointment, re-appointment/cessation (as applicable) & term of appointment, re-appointment ;	Date of Appointment – May 08, 2026 Term of Appointment – Not Applicable
d)	Brief profile (in case of appointment);	<p>Mr. Gaurav Verma is a seasoned business leader with over 19 years of experience in marketing, consumer strategy and business leadership across the healthcare, food-tech and FMCG sectors. He currently serves as Chief Business Officer at API Holdings Limited (PharmEasy), where he is responsible for driving business growth, consumer strategy, and key strategic initiatives across e-pharmacy, e-diagnostics, partnerships and other healthcare initiatives of the platform business. He previously served as Chief Marketing Officer at PharmEasy, playing a key role in brand building, customer engagement and growth during a transformative phase of the business.</p> <p>Prior to API Holdings, he held senior leadership roles at Zomato as Chief Marketing Officer, and subsequently as Global Growth Head (Dining Out). Before Zomato, he spent over nine years at PepsiCo, where he led marketing for marquee brands such as Kurkure, Lay's and Tropicana. He began his career with ITC and has also worked with Tata Tea Limited and Lenovo.</p> <p>Mr. Verma holds a Post Graduate Program in Management from the Indian Institute of Management, Bangalore, and a B.Tech in Electronics from the Indian Institute of Technology, Madras. His expertise in consumer insights, brand building and business scaling will add significant value to the Company.</p>
e)	Disclosure of relationships between directors (in case of appointment of a director).	Nil

April 30, 2026

To,
The Board of Directors,
Thyrocare Technologies Limited
D-37 /1, TTC MIDC Industrial Area,
Turbhe, Navi Mumbai - 400703
Maharashtra, India

Subject: Resignation from the Directorship of the Company

Dear Board Members,

At the outset, I wish to express my gratitude to the Company and its shareholders for the opportunity to serve as a Non-Executive Non-Independent Director on the Board of Thyrocare Technologies Limited ("the Company").


Due to preoccupation and other professional commitments, I hereby tender my resignation from the position of Non-Executive Non-Independent Director, with effect from the close of business hours on May 07, 2026. Consequently, I shall also cease to be a member of the following Board Committees with effect from the said date:

- Nomination and Remuneration Committee
- Stakeholders Relationship Committee
- Risk Management Committee

I confirm that there is no other material reason for my resignation other than what has been stated above.

I sincerely thank the Board of Directors and the management team of the Company for their continuous support and cooperation during my tenure. I wish the Company continued growth and success in the future.

Thanking you,
Yours faithfully,



Dharmil Nirupam Sheth
DIN: 06999772

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Resignation of Mr. Dharmil Nirupam Sheth (DIN: 06999772), Non-Executive, Non-Independent Director of the Company

a)	Name & Designation	Mr. Dharmil Nirupam Sheth, (DIN: 06999772) Non-Executive, Non-Independent Director
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Resignation
c)	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;	Effect from close of business hours on May 07, 2026
d)	Brief profile (in case of appointment);	Not Applicable
e)	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

April 30, 2026

To,
The Board of Directors,
Thyrocare Technologies Limited
D-37 /1, TTC MIDC Industrial Area,
Turbhe, Navi Mumbai - 400703
Maharashtra, India

Subject: Resignation from the Directorship of the Company

Dear Board Members,

At the outset, I wish to express my gratitude to the Company and its shareholders for the opportunity to serve as a Non-Executive Non-Independent Director on the Board of Thyrocare Technologies Limited ("the Company").


Due to preoccupation and other professional commitments, I hereby tender my resignation from the position of Non-Executive Non-Independent Director, with effect from the close of business hours on May 07, 2026. Consequently, I shall also cease to be a member of the following Board Committees with effect from the said date:

- Corporate Social Responsibility Committee

I confirm that there is no other material reason for my resignation other than what has been stated above.

I sincerely thank the Board of Directors and the management team of the Company for their continuous support and cooperation during my tenure. I wish the Company continued growth and success in the future.

Thanking you,
Yours faithfully,



Dhaval Shah
DIN: 07485688

Disclosure under Sub-Para (7) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Resignation of Dr. Dhaval Rajesh Shah (DIN: 07485688), Non-Executive, Non-Independent Director of the Company

a)	Name & Designation	Dr. Dhaval Rajesh Shah, (DIN: 07485688) Non-Executive, Non-Independent Director
b)	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Resignation
c)	Date of appointment/re-appointment/cessation- (as applicable) & term of appointment/re- appointment;	Effect from close of business hours on May 07, 2026
d)	Brief profile (in case of appointment);	Not Applicable
e)	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable

Disclosure under Sub-Para (1) of Para A of Part A of Schedule III to the Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Investment in the equity shares of Think Health Diagnostics Private Limited, a Wholly Owned Subsidiary of the Company

S.No	Particulars	Description
1	Name of the Target Company, details in brief such as size, turnover, etc.	Think Health Diagnostics Private Limited (“Think Health”) is a wholly owned subsidiary of the Company. Think Health is in the process of establishing a dedicated diagnostics platform, with an initial focus on affordable, high-volume testing, including thyroid and routine pathology segments. Turnover for the year ended March 31, 2026: Rs. 0.01 Crores.
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm length”	Yes, the proposed investment by way of subscription to equity shares of Think Health is a related party transaction. Except to the extent of shareholding held by the Company in Think Health, the promoters/promoter group do not have any other interest in the said entity. The transaction will be carried out at arm’s length.
3	Industry to which the entity being acquired belongs	Healthcare Services
4	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The proposed equity infusion in Think Health is intended to support its business operations and to meet its capital expenditure and working capital requirements.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not applicable
6	Indicative time for completion of the acquisition	In one or more tranches, as and when required
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash consideration
8	Cost of acquisition or the price at which the shares are acquired	Up to Rs. 5.50 crores,
9	Percentage of shareholding/ control acquired and/or number of shares acquired	No change; Think Health will continue to be a wholly owned subsidiary of the Company
10	Brief background about the entity acquired in terms of products/line of	Date of Incorporation: June 07, 2022

Tests you can trust

	business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>Think Health is focused on building a diagnostics platform with emphasis on affordable, accessible and high-volume testing services.</p> <p>Country of presence: India</p> <p>The turnover of Think Health for last 3 years is given below:</p> <table border="1" data-bbox="783 481 1252 665"><thead><tr><th data-bbox="783 481 997 555">Year</th><th data-bbox="997 481 1252 555">Turnover (Rs. in Crore)</th></tr></thead><tbody><tr><td data-bbox="783 555 997 591">2025-26</td><td data-bbox="997 555 1252 591">0.01</td></tr><tr><td data-bbox="783 591 997 627">2024-25</td><td data-bbox="997 591 1252 627">0.83</td></tr><tr><td data-bbox="783 627 997 665">2023-24</td><td data-bbox="997 627 1252 665">3.35</td></tr></tbody></table>	Year	Turnover (Rs. in Crore)	2025-26	0.01	2024-25	0.83	2023-24	3.35
Year	Turnover (Rs. in Crore)									
2025-26	0.01									
2024-25	0.83									
2023-24	3.35									